AU9281298A - Benzodioxole derivatives - Google Patents

Benzodioxole derivatives

Info

Publication number
AU9281298A
AU9281298A AU92812/98A AU9281298A AU9281298A AU 9281298 A AU9281298 A AU 9281298A AU 92812/98 A AU92812/98 A AU 92812/98A AU 9281298 A AU9281298 A AU 9281298A AU 9281298 A AU9281298 A AU 9281298A
Authority
AU
Australia
Prior art keywords
benzodioxole derivatives
benzodioxole
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU92812/98A
Inventor
Haruhiko Manabe
Hoshisuke Nakasato
Etsuo Ohshima
Koji Yanagawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Hakko Kogyo Co Ltd
Original Assignee
Kyowa Hakko Kogyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP9-268400 priority Critical
Priority to JP26840097 priority
Application filed by Kyowa Hakko Kogyo Co Ltd filed Critical Kyowa Hakko Kogyo Co Ltd
Priority to PCT/JP1998/004431 priority patent/WO1999016766A1/en
Publication of AU9281298A publication Critical patent/AU9281298A/en
Application status is Abandoned legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/72Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 spiro-condensed with carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes unsubstituted on the hetero ring
    • C07D317/62Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/64Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
AU92812/98A 1997-10-01 1998-10-01 Benzodioxole derivatives Abandoned AU9281298A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP9-268400 1997-10-01
JP26840097 1997-10-01
PCT/JP1998/004431 WO1999016766A1 (en) 1997-10-01 1998-10-01 Benzodioxole derivatives

Publications (1)

Publication Number Publication Date
AU9281298A true AU9281298A (en) 1999-04-23

Family

ID=17457959

Family Applications (1)

Application Number Title Priority Date Filing Date
AU92812/98A Abandoned AU9281298A (en) 1997-10-01 1998-10-01 Benzodioxole derivatives

Country Status (2)

Country Link
AU (1) AU9281298A (en)
WO (1) WO1999016766A1 (en)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9913405A (en) * 1998-09-03 2001-10-02 Kyowa Hakko Kogyo Kk Oxygen-containing heterocyclic compound, and phosphodiesterase inhibitor (PDE) IV.
CA2417826A1 (en) 2000-08-05 2002-02-14 Glaxo Group Limited 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
WO2002076933A1 (en) 2001-03-22 2002-10-03 Glaxo Group Limited Formailide derivatives as beta2-adrenoreceptor agonists
DE10115922A1 (en) * 2001-03-30 2002-10-10 Bayer Ag Cyclic substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and their use
HU0400070A2 (en) 2001-04-30 2004-04-28 Glaxo Group Limited 17alpha-position containing cyclic ester androstane-17.beta.-carbothioic acid ester derivatives as anti-inflammatory agents, a process for preparing the compounds and pharmaceutical compositions containing them
USRE44874E1 (en) 2001-09-14 2014-04-29 Glaxo Group Limited Phenethanolamine derivatives for treatment of respiratory diseases
ES2438985T3 (en) 2001-09-14 2014-01-21 Glaxo Group Limited Inhalation formulation comprising phenetanolamine derivatives for the treatment of respiratory diseases
WO2003091204A1 (en) 2002-04-25 2003-11-06 Glaxo Group Limited Phenethanolamine derivatives
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
PT1556342E (en) 2002-10-28 2008-04-28 Glaxo Group Ltd Phenethanolamine derivative for the treatment of respiratory diseases
PE20040950A1 (en) 2003-02-14 2005-01-01 Theravance Inc AS biphenyl derivatives adrenoceptor agonists SS2 and as antagonists of muscarinic
GB0303396D0 (en) 2003-02-14 2003-03-19 Glaxo Group Ltd Medicinal compounds
GB0316290D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
GB0317374D0 (en) 2003-07-24 2003-08-27 Glaxo Group Ltd Medicament dispenser
GB0329182D0 (en) 2003-12-17 2004-01-21 Glaxo Group Ltd Chemical compounds
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
AR049384A1 (en) 2004-05-24 2006-07-26 Glaxo Group Ltd Purine derivatives
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
GB0418045D0 (en) 2004-08-12 2004-09-15 Glaxo Group Ltd Compounds
GT200500281A (en) 2004-10-22 2006-04-24 Novartis Ag organic compounds.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
EP1841780B1 (en) 2005-01-10 2011-07-27 Glaxo Group Limited Androstane 17-alpha-carbonate derivatives for use in the treatment of allergic and inflammatory conditions
MY145281A (en) 2005-03-25 2012-01-13 Glaxo Group Ltd Novel compounds
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
NZ567124A (en) 2005-10-21 2011-08-26 Novartis Ag Human antibodies against Interleukin-13 and therapeutic uses to treat asthma
PE20071068A1 (en) 2005-12-20 2007-12-13 Glaxo Group Ltd 3- (4 - {[4- (4 - {[3- (3,3-dimethyl-1-piperidinyl) propyl] oxy} phenyl) -1-piperidinyl] carbonyl} -1-naphthalenyl) propanoic acid or propenoic salts thereof, as antagonists h1 and h3 receptors
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
ES2388351T3 (en) 2006-04-20 2012-10-11 Glaxo Group Limited novel compounds
ES2384337T3 (en) 2006-04-21 2012-07-03 Novartis Ag Purine derivatives for use as adenosine A2A receptor agonists
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
EP2081933B1 (en) 2006-09-29 2011-03-23 Novartis AG Pyrazolopyrimidines as pi3k lipid kinase inhibitors
CA2667962A1 (en) 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
DK2104535T3 (en) 2007-01-10 2011-04-04 Irm Llc Compounds and compositions as channel activating protease inhibitors
AR065804A1 (en) 2007-03-23 2009-07-01 Smithkline Beecham Corp Carboxamide indole compound, pharmaceutical composition comprising the same and use of said compound for preparing a medicament
PT2155721E (en) 2007-05-07 2011-05-09 Novartis Ag Organic compounds
UA104997C2 (en) 2007-12-10 2014-04-10 Новартіс Аг Amides of nitrogen-containing saturated heterocycles and 3,5-diamino-6-chloro-pyrazine-2-carboxylic acid as medicaments
KR20100113557A (en) 2008-01-11 2010-10-21 노파르티스 아게 Pyrimidines as kinase inhibitors
SG190667A1 (en) 2008-05-23 2013-06-28 Panmira Pharmaceuticals Llc 5-lipoxygenase-activating protein inhibitor
US8163743B2 (en) 2008-06-05 2012-04-24 GlaxoGroupLimited 4-carboxamide indazole derivatives useful as inhibitors of PI3-kinases
EP2300010B1 (en) 2008-06-10 2015-03-04 Novartis AG Pyrazine derivatives as epithelial sodium channel blockers
US20110281917A1 (en) 2009-01-29 2011-11-17 Darrin Stuart Substituted Benzimidazoles for the Treatment of Astrocytomas
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
EP2406255B1 (en) 2009-03-09 2015-04-29 Glaxo Group Limited 4-oxadiazol-2-yl-indazoles as inhibitors of pi3 kinases
EP2406249A1 (en) 2009-03-10 2012-01-18 Glaxo Group Limited Indole derivatives as ikk2 inhibitors
JP2012520845A (en) 2009-03-17 2012-09-10 グラクソ グループ リミテッドGlaxo Group Limited Pyrimidine derivatives used as Itk inhibitors
US20120035247A1 (en) 2009-03-19 2012-02-09 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 6 (STAT6) Gene Expression Using Short Interfering Nucleic Acid (siNA)
WO2010107957A2 (en) 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
MX2011009724A (en) 2009-03-19 2011-10-14 Merck Sharp & Dohme RNA INTERFERENCE MEDIATED INHIBITION OF BTB AND CNC HOMOLOGY 1, BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR 1 (BACH 1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) SEQUENCE LISTING.
US20120016011A1 (en) 2009-03-19 2012-01-19 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Connective Tissue Growth Factor (CTGF) Gene Expression Using Short Interfering Nucleic Acid (siNA)
WO2010111468A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
WO2010111464A1 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
SG174581A1 (en) 2009-03-27 2011-10-28 Merck Sharp & Dohme RNA INTERFERENCE MEDIATED INHIBITION OF THE INTERCELLULAR ADHESION MOLECULE 1 (ICAM-1)GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP2012521764A (en) 2009-03-27 2012-09-20 メルク・シャープ・エンド・ドーム・コーポレイション RNA interference-mediated inhibition of thymic stromal lymphocyte formation factor (TSLP) gene expression using small interfering nucleic acids (siNA)
WO2010111471A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
AR076373A1 (en) 2009-04-24 2011-06-08 Glaxo Group Ltd N-pyrazolyl carboxamides as inhibitors of calcium channel
WO2010122088A1 (en) 2009-04-24 2010-10-28 Glaxo Group Limited Pyrazole and triazole carboxamides as crac channel inhibitors
US8575162B2 (en) 2009-04-30 2013-11-05 Glaxosmithkline Intellectual Property Development Limited Compounds
CA2989129A1 (en) 2009-07-15 2011-01-20 Theravance Biopharma R&D Ip, Llc Crystalline freebase forms of biphenyl compound
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
BR112012003262A8 (en) 2009-08-12 2016-05-17 Novartis Ag Heterocyclic Hydrazone Compounds and Their Uses to Treat Cancer and Inflammation
TR201900259T4 (en) 2009-08-17 2019-02-21 Intellikine Llc Heterocyclic Compounds and Uses Thereof
WO2011020861A1 (en) 2009-08-20 2011-02-24 Novartis Ag Heterocyclic oxime compounds
EP2813227A1 (en) 2009-10-22 2014-12-17 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
WO2011067364A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Novel compounds
US20120238571A1 (en) 2009-12-03 2012-09-20 Glaxo Group Limited Indazole derivatives as pi 3-kinase
EP2507223A1 (en) 2009-12-03 2012-10-10 Glaxo Group Limited Benzpyrazole derivatives as inhibitors of p13 kinases
EP3020393A1 (en) 2009-12-16 2016-05-18 3M Innovative Properties Company of 3M Center Formulations and methods for controlling mdi particle size delivery
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
EP2614058B1 (en) 2010-09-08 2015-07-08 GlaxoSmithKline Intellectual Property Development Limited POLYMORPHS AND SALTS OF N-[5-[4-(5-{[(2R,6S)-2,6-DIMETHYL-4-MORPHOLINYL]METHYL}-& xA;1,3-OXAZOL-2-YL)-1H-INDAZOL-6-YL]-2-(METHYLOXY)-3-PYRIDINYL]METHANESULFONAMIDE
JP5876051B2 (en) 2010-09-08 2016-03-02 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited Indazole derivatives for use in the treatment of influenza virus infection
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
JP2013544794A (en) 2010-10-21 2013-12-19 グラクソ グループ リミテッドGlaxo Group Limited Pyrazole compounds acting on allergic disorders, inflammatory disorders and immune disorders
EP2630126B1 (en) 2010-10-21 2015-01-07 Glaxo Group Limited Pyrazole compounds acting against allergic, immune and inflammatory conditions
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
EP2673277A1 (en) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
EP2678016B1 (en) 2011-02-23 2016-08-10 Intellikine, LLC Heterocyclic compounds and uses thereof
AU2012220572A1 (en) 2011-02-25 2013-08-29 Irm Llc Compounds and compositions as trk inhibitors
GB201104153D0 (en) 2011-03-11 2011-04-27 Glaxo Group Ltd Novel compounds
WO2012123312A1 (en) 2011-03-11 2012-09-20 Glaxo Group Limited Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
US9062045B2 (en) 2011-09-15 2015-06-23 Novartis Ag Triazolopyridine compounds
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013038390A1 (en) 2011-09-16 2013-03-21 Novartis Ag N-substituted heterocyclyl carboxamides
US9034879B2 (en) 2011-09-16 2015-05-19 Novartis Ag Heterocyclic compounds for the treatment of CF
CA2856803A1 (en) 2011-11-23 2013-05-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
CA2868202A1 (en) 2012-04-03 2013-10-10 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
EP2968340A4 (en) 2013-03-15 2016-08-10 Intellikine Llc Combination of kinase inhibitors and uses thereof
CA2923995A1 (en) 2013-10-17 2015-04-23 Glaxosmithkline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
WO2015055691A1 (en) 2013-10-17 2015-04-23 Glaxosmithkline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
BR112016024484A2 (en) 2014-04-24 2017-08-15 Novartis Ag aminopyridine derivatives as phosphatidylinositol 3-kinase inhibitors
CA2945212A1 (en) 2014-04-24 2015-10-29 Novartis Ag Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
CN106458966B (en) 2014-04-24 2019-05-07 诺华股份有限公司 Pyrazines derivatives as inhibitors of phosphatidylinositol3 3-kinase
EA201692111A1 (en) 2014-05-12 2017-08-31 Глаксосмитклайн Интеллекчуал Проперти (№ 2) Лимитед Pharmaceutical compositions containing daniryxin for treating infectious diseases
JP6526789B2 (en) 2014-07-31 2019-06-05 ノバルティス アーゲー Combination therapy
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
JP2019524792A (en) 2016-08-08 2019-09-05 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited Compound
US20190307975A1 (en) 2016-11-21 2019-10-10 Lupin Inc. Medicament dispenser
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
GB201712081D0 (en) 2017-07-27 2017-09-13 Glaxosmithkline Ip Dev Ltd Chemical compounds
WO2019195711A1 (en) 2018-04-06 2019-10-10 Lupin Inc. Medicament dispenser

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU202854B (en) * 1986-05-27 1991-04-29 Tsumura & Co Process for producing new biphenyl derivatives and pharmaceutical compositions comprising such compounds as active ingredient

Also Published As

Publication number Publication date
WO1999016766A1 (en) 1999-04-08

Similar Documents

Publication Publication Date Title
EP0882553B8 (en) Knife
EG23729A (en) N-alkanoylphenylalanine derivatives
EG24081A (en) 4-Substituted-9-deoxo-9a-aza-9a-homerythromycin derivatives
AU690879B1 (en) Earphone
AU740792C (en) Benzimidazole derivatives
AU742928C (en) N-alkanoylphenylalanine derivatives
AU1589300A (en) Autoinjector
AU3292095A (en) Cycloalkano-indole and -azaindole derivatives
AU9623898A (en) Vaccines
AU5782798A (en) Gemcitabine derivatives
AU1507199A (en) Novel pyrimidine-5-carboxamide derivatives
AU6498798A (en) Toothbrush
AU2070795A (en) 3-aryl-4-hydroxy-delta3-dihydrothiophenone derivatives
AU6873398A (en) Table construction
AU1405500A (en) An exsanguinator
AU5844998A (en) Microemulsion
HRP980062A2 (en) N-hydroxy-beta-sulfonyl-propionamide derivatives
GB9702194D0 (en) Sulphonide derivatives
AU5728999A (en) Heterominibodies
AU6243298A (en) Planting unit
PL195240B1 (en) Substituted 3-heterocyclyl-benzoyl derivatives
AU6280098A (en) 2-alkyl-19-nor-vitamin d compounds
AU1554897A (en) 6-phenylpyridyl-2-amine derivatives
AU7221298A (en) Compounds
AU757630C (en) Novel aryloxy-alkyl-dialkylamines

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase